Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data
Headache The Journal of Head and Face Pain2021Vol. 61(9), pp. 1411–1420
Citations Over TimeTop 10% of 2021 papers
David W. Dodick, Stewart J. Tepper, Jessica Ailani, Nicola Pannacciulli, Marco S. Navetta, Brett Loop, Feng Zhang, Ani C. Khodavirdi, Allison Mann, Ahmad Abdrabboh, Jawed Kalim
Abstract
Clinical trials did not demonstrate an increased risk of hypertension with erenumab compared with placebo, and AE rates of hypertension reported with erenumab in the postmarketing setting were generally low. Additional data are needed to fully characterize the extent to which hypertension is a risk associated with erenumab.
Related Papers
- → The role of concomitant headache types and non-headache co-morbidities in the underdiagnosis of migraine(2002)85 cited
- → The role of concomitant headache types and non‐headache co‐morbidities in the underdiagnosis of migraine.(2003)16 cited
- → TOTAL 5-HYDROXYINDOLES IN BLOOD RELATED to MIGRAINE ATTACKS(1976)14 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- [Migraine and the influence of hormones].(2008)